MA35664B1 - Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one - Google Patents
Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-oneInfo
- Publication number
- MA35664B1 MA35664B1 MA37074A MA37074A MA35664B1 MA 35664 B1 MA35664 B1 MA 35664B1 MA 37074 A MA37074 A MA 37074A MA 37074 A MA37074 A MA 37074A MA 35664 B1 MA35664 B1 MA 35664B1
- Authority
- MA
- Morocco
- Prior art keywords
- dihydroisoquinolin
- bicyclic derivatives
- new bicyclic
- new
- derivatives
- Prior art date
Links
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouveaux composés de formule générale (i). Dans la formule générale, r
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011083229 | 2011-11-30 | ||
| PCT/EP2012/073653 WO2013079452A1 (fr) | 2011-11-30 | 2012-11-27 | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35664B1 true MA35664B1 (fr) | 2014-11-01 |
Family
ID=47297189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37074A MA35664B1 (fr) | 2011-11-30 | 2014-05-27 | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9133158B2 (fr) |
| EP (2) | EP3587401A1 (fr) |
| JP (1) | JP6382108B2 (fr) |
| KR (1) | KR102089927B1 (fr) |
| AR (1) | AR088989A1 (fr) |
| AU (1) | AU2012344041B2 (fr) |
| BR (1) | BR112014013136B1 (fr) |
| CA (1) | CA2850700C (fr) |
| CL (1) | CL2014001389A1 (fr) |
| CO (1) | CO6920296A2 (fr) |
| CR (1) | CR20140229A (fr) |
| DK (1) | DK2785695T3 (fr) |
| EA (1) | EA035454B1 (fr) |
| ES (1) | ES2811806T3 (fr) |
| HR (1) | HRP20201277T1 (fr) |
| HU (1) | HUE050431T2 (fr) |
| IL (1) | IL232570B (fr) |
| LT (1) | LT2785695T (fr) |
| MA (1) | MA35664B1 (fr) |
| MX (1) | MX350717B (fr) |
| MY (1) | MY178867A (fr) |
| PE (1) | PE20141283A1 (fr) |
| PH (1) | PH12014501179B1 (fr) |
| PL (1) | PL2785695T3 (fr) |
| PT (1) | PT2785695T (fr) |
| RS (1) | RS60660B1 (fr) |
| SG (1) | SG11201402199QA (fr) |
| SI (1) | SI2785695T1 (fr) |
| TW (1) | TWI583678B (fr) |
| UA (1) | UA112565C2 (fr) |
| WO (1) | WO2013079452A1 (fr) |
| ZA (1) | ZA201402908B (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| EP2989082A1 (fr) * | 2013-04-23 | 2016-03-02 | LEK Pharmaceuticals d.d. | Nouveau procédé de synthèse de 8-chloro-1-méthyl-benzo[d]azépine, nouveaux intermédiaires et leur production |
| CN105209470B (zh) * | 2013-05-17 | 2018-02-06 | 豪夫迈·罗氏有限公司 | 用于治疗和预防乙型肝炎病毒感染的6‑桥连的杂芳基二氢嘧啶 |
| JP6581970B2 (ja) * | 2013-05-27 | 2019-09-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規３，４−ジヒドロ−２ｈ−イソキノリン−１−オン及び２，３−ジヒドロ−イソインドール−１−オン化合物 |
| MY176401A (en) | 2014-04-24 | 2020-08-05 | Mitsubishi Tanabe Pharma Corp | Novel disubstituted 1,2,4-triazine compound |
| PE20171057A1 (es) * | 2014-10-08 | 2017-07-21 | Hoffmann La Roche | Derivados espirodiamina como inhibidores de la aldosterona sintasa |
| AP2017009829A0 (en) * | 2014-10-15 | 2017-03-31 | Boehringer Ingelheim Int | Aldosterone synthase inhibitors |
| US10759791B2 (en) | 2014-11-04 | 2020-09-01 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
| WO2016089800A1 (fr) * | 2014-12-02 | 2016-06-09 | Boehringer Ingelheim International Gmbh | Inhibiteurs de l'aldostérone synthase |
| JP6314196B2 (ja) * | 2015-10-22 | 2018-04-18 | 田辺三菱製薬株式会社 | 医薬組成物 |
| EP3381904B1 (fr) * | 2015-10-23 | 2021-07-28 | Mitsubishi Tanabe Pharma Corporation | Nouveau composé hétérocyclique aromatique contenant de l'azote |
| AU2016379292B2 (en) | 2015-12-24 | 2021-03-25 | Kyowa Kirin Co., Ltd. | α, β unsaturated amide compound |
| EP3509588B1 (fr) | 2016-09-12 | 2023-06-07 | Integral Health,Inc. | Composés bicycliques utiles en tant que modulateurs du gpr120 |
| WO2018049324A1 (fr) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Composés monocycliques utiles comme modulateurs de gpr120 |
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| WO2018235926A1 (fr) | 2017-06-23 | 2018-12-27 | 協和発酵キリン株式会社 | COMPOSÉ AMIDE α, β-INSATURÉ |
| US20210147381A1 (en) | 2017-07-17 | 2021-05-20 | AbbVie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as sip modulators |
| CN109810171B (zh) * | 2017-11-21 | 2020-12-01 | 首都医科大学 | 二氢异喹啉-3-甲酰-LARGD(aa)aa,其制备,抗静脉血栓活性和应用 |
| CN111801314B (zh) | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
| CN111051309B (zh) * | 2018-06-26 | 2023-05-26 | 浙江春禾医药科技有限公司 | 可用作a2a受体拮抗剂的三唑并三嗪衍生物 |
| HU231223B1 (hu) | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
| JP7530384B2 (ja) | 2019-05-01 | 2024-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | （ｒ）－（２－メチルオキシラン－２－イル）メチル ４－ブロモベンゼンスルホネート |
| WO2021032935A1 (fr) * | 2019-08-21 | 2021-02-25 | Kalvista Pharmaceuticals Limited | Inhibiteurs d'enzyme |
| WO2021224818A1 (fr) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Composés d'isoindolone en tant qu'inhibiteurs de hpk1 |
| WO2023063851A1 (fr) * | 2021-10-13 | 2023-04-20 | «Target Medicals» Limited Liability Company | Inhibiteurs de l'aldostérone synthase humaine (cyp11b2) |
| US12213973B2 (en) | 2021-10-18 | 2025-02-04 | Northwestern University | Bacterial nitric oxide synthase inhibitors |
| CA3236890A1 (fr) | 2021-12-14 | 2023-06-22 | Boehringer Ingelheim International Gmbh | Inhibiteurs de l'aldosterone synthase pour le traitement d'une nephropathie chronique |
| EP4574830A4 (fr) * | 2022-09-23 | 2025-11-26 | Guangzhou Vinnocent Pharmaceutical Ltd | Inhibiteur de pyridine stéroïde synthétase annelée, son procédé de préparation et son utilisation |
| AU2023378302A1 (en) * | 2022-11-10 | 2025-04-10 | «Target Medicals» Limited Liability Company | Inhibitors of human aldosterone synthase (cyp11b2) |
| CN117247371B (zh) * | 2023-09-18 | 2026-03-10 | 上海相辉医药科技有限公司 | 一种cyp11b2抑制剂baxdrostat的制备方法 |
| CN121135736A (zh) * | 2024-03-01 | 2025-12-16 | 浙江扬厉医药技术有限公司 | 吡喃并吡啶类化合物、其制备方法、药物组合物及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT79699B (en) | 1983-12-22 | 1986-12-10 | Pfizer | Process for preparing quinolone inotropic agents |
| AU2002306596B2 (en) * | 2001-02-27 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2007117982A2 (fr) * | 2006-03-29 | 2007-10-18 | Novartis Ag | Composés organiques |
| JP5241834B2 (ja) * | 2007-07-19 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインキナーゼ阻害剤としての複素環アミド化合物 |
| TW200918062A (en) * | 2007-09-12 | 2009-05-01 | Wyeth Corp | Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| EP2430011A1 (fr) * | 2009-05-15 | 2012-03-21 | Novartis AG | Dérivés de 5-pyridin-3-yl-1,3-dihydro-indol-2-on et leur utilisation en tant que modulateurs de l'aldostérone synthase et/ou de la cyp11b1 |
| US8946260B2 (en) * | 2010-09-16 | 2015-02-03 | Novartis Ag | 17α-hydroxylase/C17,20-lyase inhibitors |
-
2012
- 2012-11-27 BR BR112014013136-8A patent/BR112014013136B1/pt not_active IP Right Cessation
- 2012-11-27 EP EP19187075.7A patent/EP3587401A1/fr active Pending
- 2012-11-27 MY MYPI2014701399A patent/MY178867A/en unknown
- 2012-11-27 PE PE2014000766A patent/PE20141283A1/es active IP Right Grant
- 2012-11-27 HR HRP20201277TT patent/HRP20201277T1/hr unknown
- 2012-11-27 DK DK12797817.9T patent/DK2785695T3/da active
- 2012-11-27 AU AU2012344041A patent/AU2012344041B2/en not_active Ceased
- 2012-11-27 CA CA2850700A patent/CA2850700C/fr active Active
- 2012-11-27 KR KR1020147018023A patent/KR102089927B1/ko not_active Expired - Fee Related
- 2012-11-27 JP JP2014543854A patent/JP6382108B2/ja active Active
- 2012-11-27 SI SI201231822T patent/SI2785695T1/sl unknown
- 2012-11-27 MX MX2014005833A patent/MX350717B/es active IP Right Grant
- 2012-11-27 LT LTEP12797817.9T patent/LT2785695T/lt unknown
- 2012-11-27 AR ARP120104439A patent/AR088989A1/es active IP Right Grant
- 2012-11-27 RS RS20200979A patent/RS60660B1/sr unknown
- 2012-11-27 WO PCT/EP2012/073653 patent/WO2013079452A1/fr not_active Ceased
- 2012-11-27 EP EP12797817.9A patent/EP2785695B1/fr active Active
- 2012-11-27 EA EA201491018A patent/EA035454B1/ru not_active IP Right Cessation
- 2012-11-27 SG SG11201402199QA patent/SG11201402199QA/en unknown
- 2012-11-27 ES ES12797817T patent/ES2811806T3/es active Active
- 2012-11-27 PL PL12797817T patent/PL2785695T3/pl unknown
- 2012-11-27 UA UAA201407120A patent/UA112565C2/uk unknown
- 2012-11-27 HU HUE12797817A patent/HUE050431T2/hu unknown
- 2012-11-27 PT PT127978179T patent/PT2785695T/pt unknown
- 2012-11-29 US US13/688,373 patent/US9133158B2/en active Active
- 2012-11-29 TW TW101144851A patent/TWI583678B/zh not_active IP Right Cessation
-
2014
- 2014-03-31 CO CO14068498A patent/CO6920296A2/es active IP Right Grant
- 2014-04-22 ZA ZA2014/02908A patent/ZA201402908B/en unknown
- 2014-05-12 IL IL232570A patent/IL232570B/en active IP Right Grant
- 2014-05-15 CR CR20140229A patent/CR20140229A/es unknown
- 2014-05-26 PH PH12014501179A patent/PH12014501179B1/en unknown
- 2014-05-27 CL CL2014001389A patent/CL2014001389A1/es unknown
- 2014-05-27 MA MA37074A patent/MA35664B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
| MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
| MA35049B1 (fr) | Triazolopyridines | |
| MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
| MA37756A1 (fr) | Nouveaux composés diazaspirocycloalcane et azaspirocycloalcane | |
| MA35357B1 (fr) | Composes de type anilines | |
| MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
| CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
| EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
| EA201490567A1 (ru) | Новые бициклические производные дигидрохинолин-2-она | |
| MA35086B1 (fr) | Compose de triazolopyridine | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| AU2011232516A8 (en) | Chemical compounds | |
| MA38432A1 (fr) | Nouveaux dérivés d'octahydro-pyrrolo [3,4-c]-pyrrole et analogues de ceux-ci servant d'inhibiteurs d'autotaxine | |
| CR20140042A (es) | Indazoles | |
| UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
| AU2014270524A8 (en) | 2-phenylimidazo [1,2-a]pyrimidines as imaging agents | |
| AU2012213775A8 (en) | 7-azaindole derivatives | |
| EA201591527A1 (ru) | Новые производные пиридина | |
| PE20120495A1 (es) | 3-ciclopentilamino-2,2-difluor-propanoato de etilo como intermediario en la preparacion de pirimidodiazepinas | |
| MX350892B (es) | Síntesis de compuesto antiviral. | |
| EA201490474A1 (ru) | Аминохиназолины в качестве ингибиторов киназ | |
| EA201491002A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| UA113062C2 (xx) | Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону |